XLH UK is delighted to report that adults living with XLH in England, Wales and Northern Ireland will now have access to burosumab, the first available treatment to tackle the underlying cause of XLH.

The decision by NICE ensures equal access to burosumab across the UK, as adults living with XLH in Scotland have been able to benefit since February 2023.

For further information, see our press release or watch our online webinar here.